Insight Capital Research & Management Inc. lowered its stake in shares of Cynosure Inc. (NASDAQ:CYNO) by 4.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 118,116 shares of the company’s stock after selling 5,147 shares during the period. Cynosure makes up 2.0% of Insight Capital Research & Management Inc.’s holdings, making the stock its 4th largest position. Insight Capital Research & Management Inc.’s holdings in Cynosure were worth $5,746,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the stock. Falcon Point Capital LLC raised its position in shares of Cynosure by 0.8% in the second quarter. Falcon Point Capital LLC now owns 348,360 shares of the company’s stock worth $16,946,000 after buying an additional 2,636 shares during the period. Capstone Asset Management Co. raised its position in shares of Cynosure by 17.3% in the second quarter. Capstone Asset Management Co. now owns 10,916 shares of the company’s stock worth $531,000 after buying an additional 1,610 shares during the period. Prudential Financial Inc. raised its position in shares of Cynosure by 4.7% in the first quarter. Prudential Financial Inc. now owns 55,278 shares of the company’s stock worth $2,439,000 after buying an additional 2,500 shares during the period. Barclays PLC raised its position in shares of Cynosure by 170,900.0% in the first quarter. Barclays PLC now owns 17,100 shares of the company’s stock worth $752,000 after buying an additional 17,090 shares during the period. Finally, Aristotle Capital Boston LLC raised its position in shares of Cynosure by 9.1% in the first quarter. Aristotle Capital Boston LLC now owns 73,789 shares of the company’s stock worth $3,256,000 after buying an additional 6,175 shares during the period. 99.51% of the stock is owned by institutional investors.
Cynosure Inc. (NASDAQ:CYNO) traded up 0.65% during midday trading on Friday, reaching $50.94. The company’s stock had a trading volume of 210,489 shares. The firm has a 50-day moving average price of $51.88 and a 200 day moving average price of $48.97. Cynosure Inc. has a 52-week low of $29.98 and a 52-week high of $55.94. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of 60.14 and a beta of 1.54.
Cynosure (NASDAQ:CYNO) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.07. The firm earned $110.30 million during the quarter, compared to analysts’ expectations of $101.31 million. Cynosure had a net margin of 5.09% and a return on equity of 6.57%. The company’s revenue for the quarter was up 31.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.30 earnings per share. Equities research analysts predict that Cynosure Inc. will post $1.34 EPS for the current fiscal year.
A number of equities analysts recently issued reports on CYNO shares. Zacks Investment Research lowered Cynosure from a “hold” rating to a “sell” rating in a report on Tuesday, June 28th. Brean Capital set a $60.00 price objective on Cynosure and gave the stock a “buy” rating in a report on Wednesday, September 14th. Maxim Group increased their price objective on Cynosure from $60.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, July 27th. Stifel Nicolaus reissued a “buy” rating and issued a $62.00 price objective (up from $57.00) on shares of Cynosure in a report on Wednesday, July 27th. Finally, Northland Securities set a $60.00 price objective on Cynosure and gave the stock a “buy” rating in a report on Wednesday, July 27th. Seven equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $61.40.
In other Cynosure news, Chairman Michael R. Davin sold 4,222 shares of the firm’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $53.18, for a total transaction of $224,525.96. Following the completion of the transaction, the chairman now owns 4,222 shares in the company, valued at $224,525.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Timothy W. Baker sold 5,834 shares of the firm’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $53.35, for a total transaction of $311,243.90. Following the transaction, the chief financial officer now owns 5,834 shares of the company’s stock, valued at approximately $311,243.90. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.
Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.
Want to see what other hedge funds are holding CYNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cynosure Inc. (NASDAQ:CYNO).
Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.